[go: up one dir, main page]

CY1120024T1 - Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης - Google Patents

Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης

Info

Publication number
CY1120024T1
CY1120024T1 CY20181100284T CY181100284T CY1120024T1 CY 1120024 T1 CY1120024 T1 CY 1120024T1 CY 20181100284 T CY20181100284 T CY 20181100284T CY 181100284 T CY181100284 T CY 181100284T CY 1120024 T1 CY1120024 T1 CY 1120024T1
Authority
CY
Cyprus
Prior art keywords
alkyl
compounds
pyrimidinyl
halogen
formula
Prior art date
Application number
CY20181100284T
Other languages
English (en)
Inventor
Christine F. GELIN
Terry P. LEBOLD
Brock T. Shireman
Jeannie M. ZIFF
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1120024T1 publication Critical patent/CY1120024T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε ενώσεις του Τύπου I: όπου Χ είναι Ν ή CR1• Υ είναι Ν ή CR2• R1 είναι Η, αλκόξυ, αλογόνο, τριαζολύλ, πυριμιδινύλ, οξαζολύλ, ισοξαζόλιο, οξαδιαζολύλ ή πυραζολύλ• R2 είναι Η, αλκύλ, αλκόξυ ή αλογόνο• Ζ είναι ΝΗ ή Ο• R3 είναι Η, αλκύλ, αλκόξυ, αλογόνο ή τριαζολύλ• R4 είναι Η ή αλκύλ• ή R3 και R4, μαζί με τα άτομα προς τα οποία συνδέονται, σχηματίζουν 6-μελή αρύλ δακτύλιο ή 5-μελή ή 6-μελή ετεροαρύλ δακτύλιο• R5 είναι πυριδύλ, πυραζινύλ ή πυριμιδινύλ, όπου η πυριδύλ, πυραζινύλ ή πυριμιδινύλ προαιρετικώς είναι υποκατεστημένη με αλογόνο ή αλκύλ• και n είναι 1 ή 2. Μέθοδοι κατασκευής των ενώσεων του Τύπου I επίσης περιγράφονται. Η εφεύρεση επίσης αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν ενώσεις του Τύπου I. Μέθοδοι χρήσης των ενώσεων της εφεύρεσης επίσης ευρίσκονται εντός του σκοπού της εφεύρεσης.
CY20181100284T 2013-03-13 2018-03-09 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης CY1120024T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
PCT/US2014/024293 WO2014165070A1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators

Publications (1)

Publication Number Publication Date
CY1120024T1 true CY1120024T1 (el) 2018-12-12

Family

ID=50487148

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20181100284T CY1120024T1 (el) 2013-03-13 2018-03-09 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης
CY20191101261T CY1122392T1 (el) 2013-03-13 2019-12-02 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης
CY20231100361T CY1126106T1 (el) 2013-03-13 2023-07-25 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20191101261T CY1122392T1 (el) 2013-03-13 2019-12-02 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης
CY20231100361T CY1126106T1 (el) 2013-03-13 2023-07-25 Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης

Country Status (39)

Country Link
US (5) US9611277B2 (el)
EP (4) EP2970314B1 (el)
JP (1) JP6275815B2 (el)
KR (1) KR102209424B1 (el)
CN (3) CN105308048B (el)
AR (1) AR095423A1 (el)
AU (2) AU2014248680B2 (el)
BR (1) BR112015022294B1 (el)
CA (1) CA2904618C (el)
CL (1) CL2015002609A1 (el)
CR (2) CR20210523A (el)
CY (3) CY1120024T1 (el)
DK (2) DK2970314T3 (el)
EA (1) EA029276B1 (el)
ES (3) ES2950032T3 (el)
HK (1) HK1219725A1 (el)
HR (3) HRP20230633T1 (el)
HU (3) HUE047592T2 (el)
IL (2) IL240466B (el)
JO (1) JOP20140092B1 (el)
LT (2) LT3363438T (el)
ME (2) ME03572B (el)
MX (2) MX361529B (el)
MY (1) MY183725A (el)
NI (1) NI201500130A (el)
NO (1) NO3107630T3 (el)
PE (1) PE20151599A1 (el)
PH (1) PH12015501929B1 (el)
PL (3) PL2970314T3 (el)
PT (2) PT2970314T (el)
RS (3) RS56875B1 (el)
SG (1) SG11201507415QA (el)
SI (2) SI3363438T1 (el)
SM (3) SMT202300223T1 (el)
TW (1) TWI621618B (el)
UA (1) UA118669C2 (el)
UY (1) UY35409A (el)
WO (1) WO2014165070A1 (el)
ZA (1) ZA201507562B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022766B1 (ru) 2009-10-23 2016-02-29 Янссен Фармацевтика Нв ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
MX2016011549A (es) * 2014-03-06 2017-05-08 Shanghai Haiyan Pharmaceutical Tech Co Ltd Derivados de piperidina como antagonistas de receptores de orexina.
JP6715239B2 (ja) * 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106349228B (zh) 2015-07-17 2019-07-09 广东东阳光药业有限公司 取代的喹唑啉酮类化合物及其制备方法和用途
WO2017028732A1 (zh) * 2015-08-14 2017-02-23 上海海雁医药科技有限公司 食欲素受体拮抗剂化合物的晶型及其制备方法和应用
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
PT4122464T (pt) 2017-03-28 2024-06-27 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças do fígado
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN111315734B (zh) * 2017-09-01 2024-03-08 克罗诺斯治疗有限公司 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020123925A1 (en) * 2018-12-14 2020-06-18 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof
IL284591B1 (en) 2019-01-15 2024-12-01 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
AU2003202753A1 (en) 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
JP2006518367A (ja) 2003-02-21 2006-08-10 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー エキソ−（ｔ−ブチル２Ｒ（＋））−２−アミノ−７−アザビシクロ［２．２．１］ヘプタン−７−カルボキシレート、中間体、およびそれらを製造および単離する方法
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
EP2094685B1 (en) 2006-12-01 2011-01-19 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AU2008260647A1 (en) * 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
SI2170864T1 (sl) 2007-07-17 2012-04-30 Bristol Myers Squibb Co Piridon gpr119g proteinsko povezani receptorski antagonisti
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
NZ588080A (en) * 2008-02-21 2012-04-27 Actelion Pharmaceuticals Ltd 2-Aza-bicyclo[2.2.1]heptane derivatives
JP2011519849A (ja) 2008-04-30 2011-07-14 アクテリオン ファーマシューティカルズ リミテッド ピペリジン及びピロリジン化合物
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
EA201170742A1 (ru) 2008-12-02 2012-01-30 Глэксо Груп Лимитед Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
BRPI1013933A2 (pt) 2009-04-24 2017-06-13 Glaxo Group Ltd 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EA022766B1 (ru) 2009-10-23 2016-02-29 Янссен Фармацевтика Нв ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
AU2010332010A1 (en) 2009-12-14 2012-08-02 Inspire Pharmaceuticals, Inc. Bridged bicyclic Rho kinase inhibitor compounds, composition and use
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014066196A1 (en) 2012-10-23 2014-05-01 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
MX2015006191A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
CN106458985B (zh) 2014-02-06 2019-05-03 艾伯维公司 6-杂芳氧基-和6-芳氧基-喹啉-2-甲酰胺及其用途
JP6715239B2 (ja) 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用

Also Published As

Publication number Publication date
NI201500130A (es) 2015-11-30
CL2015002609A1 (es) 2016-03-28
US8969352B2 (en) 2015-03-03
US9611277B2 (en) 2017-04-04
CY1126106T1 (el) 2023-11-15
TW201446757A (zh) 2014-12-16
CR20210523A (es) 2021-11-19
HRP20192032T1 (hr) 2020-02-07
US20170204096A1 (en) 2017-07-20
CN105308048B (zh) 2019-10-08
PH12015501929A1 (en) 2016-01-04
LT2970314T (lt) 2018-02-12
PL3622956T3 (pl) 2023-09-18
SMT201800056T1 (it) 2018-03-08
US20170015651A1 (en) 2017-01-19
CR20150433A (es) 2015-10-26
AU2014248680A1 (en) 2015-08-27
RS59466B1 (sr) 2019-11-29
PL3363438T3 (pl) 2020-02-28
HUE036193T2 (hu) 2018-06-28
EP4272824A3 (en) 2024-01-10
US10183953B2 (en) 2019-01-22
TWI621618B (zh) 2018-04-21
DK3363438T3 (da) 2019-11-11
EP2970314B1 (en) 2017-12-13
US20150174129A1 (en) 2015-06-25
HUE047592T2 (hu) 2020-05-28
EA029276B1 (ru) 2018-03-30
BR112015022294A2 (pt) 2017-07-18
RS56875B1 (sr) 2018-04-30
DK2970314T3 (en) 2018-02-26
PH12015501929B1 (en) 2016-01-04
EP3363438B1 (en) 2019-09-18
SMT201900655T1 (it) 2020-01-14
WO2014165070A1 (en) 2014-10-09
ES2950032T3 (es) 2023-10-04
EP3363438A1 (en) 2018-08-22
CN110669052A (zh) 2020-01-10
IL240466A0 (en) 2015-09-24
AR095423A1 (es) 2015-10-14
BR112015022294B1 (pt) 2022-09-13
HRP20180303T1 (hr) 2018-03-23
MX2015011815A (es) 2016-11-07
ME03011B (me) 2018-10-20
NZ710872A (en) 2020-10-30
PT3363438T (pt) 2019-12-11
NO3107630T3 (el) 2018-01-06
US20140275118A1 (en) 2014-09-18
US20160052939A1 (en) 2016-02-25
KR20150126694A (ko) 2015-11-12
MX361529B (es) 2018-12-07
AU2014248680B2 (en) 2018-07-26
CN105308048A (zh) 2016-02-03
ZA201507562B (en) 2019-04-24
LT3363438T (lt) 2019-11-11
SMT202300223T1 (it) 2023-09-06
CY1122392T1 (el) 2021-01-27
HUE063608T2 (hu) 2024-01-28
RS64551B9 (sr) 2023-12-29
SI2970314T1 (en) 2018-02-28
AU2018204835A1 (en) 2018-07-19
EP3622956A1 (en) 2020-03-18
ES2760564T3 (es) 2020-05-14
KR102209424B1 (ko) 2021-01-29
CN110669052B (zh) 2022-10-11
SI3363438T1 (sl) 2019-11-29
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
JP2016512535A (ja) 2016-04-28
JP6275815B2 (ja) 2018-02-07
JOP20140092B1 (ar) 2021-08-17
IL264606A (en) 2019-02-28
CA2904618A1 (en) 2014-10-09
EP3622956B9 (en) 2023-09-27
ES2659397T3 (es) 2018-03-15
CN108864093A (zh) 2018-11-23
AU2018204835B2 (en) 2019-08-08
EP4272824A2 (en) 2023-11-08
PT2970314T (pt) 2018-03-05
MY183725A (en) 2021-03-10
IL240466B (en) 2019-03-31
EP3622956B1 (en) 2023-06-07
UY35409A (es) 2014-09-30
MX368466B (es) 2019-10-03
HRP20230633T1 (hr) 2023-09-29
CA2904618C (en) 2021-12-07
EP3622956C0 (en) 2023-06-07
US9845333B2 (en) 2017-12-19
SG11201507415QA (en) 2015-10-29
UA118669C2 (uk) 2019-02-25
ME03572B (me) 2020-07-20
HK1219725A1 (zh) 2017-04-13
RS64551B1 (sr) 2023-10-31
PE20151599A1 (es) 2015-11-12
PL2970314T3 (pl) 2018-05-30
US9447117B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
CY1120024T1 (el) Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1121047T1 (el) Ενωσεις αμιδιου για τη θεραπεια toy hiv
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
CY1120066T1 (el) Ενωση κινολονης
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
CY1117374T1 (el) Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1123154T1 (el) Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
CY1122196T1 (el) Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
CY1118164T1 (el) Διεργασια για την παραγωγη ενδιαμεσων οιστετρολης
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
CY1118883T1 (el) Μεθοδος παρασκευης βορτιοξετινης
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
MX2021011971A (es) Proceso para preparar cicloserinas sustituidas.
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.